Hemispherx Joins The Ebola Game
This was a recent headline from earlier this week: "Hemispherx Announces Strategic Relationship with Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola"
While a lot of attention has been paid to names such as Tekmira Pharmaceuticals, most are not familiar with the likes of Hemispherx.
What everyone is familiar with is the current Ebola scare. News of the virus dominates the networks, and when it comes to the stock market any biotech names associated with Ebola are getting attention.
So, headlines like the one above are certainly worth taking a closer look at to see if the company in question might be worth making an investment in.
The Company: Hemispherx Biopharma, Inc.
Ticker Symbol: (NYSE: HEB)
Sector: Health care
Hemispherx Biopharma is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based chronic disorders.
Related Link: The Strongest Biotech Stock in the Market
Hemispherx currently is testing its experimental immunomodulator Ampligen for potential efficacy as a prophylactic and therapeutic against the Ebola virus.
Take a look at the one-year chart of Hemispherx with added notations:
Hemispherx had trended primarily lower from the start of the year until July. Since then, a rally has ensued.
The stock has created a series of higher highs and higher lows as it has slowly moved from around 0.26 to a recent high of $0.40.
The stock is moving higher and is an inexpensive way to invest in Ebola vaccines should the virus continue to spread.
The stock closed Tuesday at $0.32.
Always remember to use protective stops, and you’ll be around for the next trade. Capital preservation is always key.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.